Cytokine Changes and Tryptophan Metabolites in Medication-Naive and Medication-Free Schizophrenic Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Yong-Ku | - |
dc.contributor.author | Myint, Aye-Mu | - |
dc.contributor.author | Verkerk, Robert | - |
dc.contributor.author | Scharpe, Simon | - |
dc.contributor.author | Steinbusch, Harry | - |
dc.contributor.author | Leonard, Brian | - |
dc.date.accessioned | 2021-09-09T01:01:03Z | - |
dc.date.available | 2021-09-09T01:01:03Z | - |
dc.date.created | 2021-06-10 | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0302-282X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/122096 | - |
dc.description.abstract | Cytokine imbalances especially between T helper type (Th) 1 and Th2 and tryptophan breakdown were reported to be involved in the pathophysiology of schizophrenia. The hyperactive inflammatory response system could induce enhanced tryptophan breakdown. This study aimed to investigate the relationship between cytokine changes, tryptophan breakdown parameter changes and clinical parameters in patients with schizophrenia in comparison with normal controls. In the plasma of schizophrenic patients, Th1-specific interferon-gamma was significantly higher (F = 7.485, p = 0.007) and Th2-specific interleukin (IL)-4 was significantly lower (F = 126.327, p < 0.0001). The Th1-related cytokine IL-2 was lower (F = 5.409, p = 0.021) but tumor necrosis factor-alpha (TNF-alpha) and Th2-related IL-6 were higher (F = 95.004, p < 0.0001 and F = 408.176, p < 0.0001, respectively) in the plasma of schizophrenic patients. After 6 weeks of treatment, IL-6 and TNF-alpha were significantly reduced (t = -3.762, p < 0.0001 and z = -2.668, p = 0.008). At the time of admission, plasma tryptophan concentrations were lower (F = 6.339, p = 0.012) in schizophrenic patients and were negatively correlated with the total positive symptoms score (r(2) = -0.343, p = 0.004). After 6 weeks of medication, both plasma tryptophan and kynurenine concentrations were increased (t = -2.937, p = 0.005 and t = -3.214, p = 0.002, respectively). The findings of this study indicate a hyperactive pro-inflammatory response inducing a change in tryptophan metabolism that might be related to the development of positive symptoms in schizophrenia. Copyright (C) 2009 S. Karger AG, Basel | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KARGER | - |
dc.subject | INDOLEAMINE 2,3-DIOXYGENASE ACTIVITY | - |
dc.subject | PERFORMANCE LIQUID-CHROMATOGRAPHY | - |
dc.subject | HUMAN MONONUCLEAR PHAGOCYTES | - |
dc.subject | RAT-LIVER CELLS | - |
dc.subject | CLOZAPINE TREATMENT | - |
dc.subject | ADJUNCTIVE THERAPY | - |
dc.subject | COX-2 INHIBITORS | - |
dc.subject | INTERFERON-GAMMA | - |
dc.subject | SEROTONIN | - |
dc.subject | PATHWAY | - |
dc.title | Cytokine Changes and Tryptophan Metabolites in Medication-Naive and Medication-Free Schizophrenic Patients | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yong-Ku | - |
dc.identifier.doi | 10.1159/000213565 | - |
dc.identifier.scopusid | 2-s2.0-65449120384 | - |
dc.identifier.wosid | 000265418000050 | - |
dc.identifier.bibliographicCitation | NEUROPSYCHOBIOLOGY, v.59, no.2, pp.123 - 129 | - |
dc.relation.isPartOf | NEUROPSYCHOBIOLOGY | - |
dc.citation.title | NEUROPSYCHOBIOLOGY | - |
dc.citation.volume | 59 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 123 | - |
dc.citation.endPage | 129 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalResearchArea | Psychology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Psychology | - |
dc.subject.keywordPlus | INDOLEAMINE 2,3-DIOXYGENASE ACTIVITY | - |
dc.subject.keywordPlus | PERFORMANCE LIQUID-CHROMATOGRAPHY | - |
dc.subject.keywordPlus | HUMAN MONONUCLEAR PHAGOCYTES | - |
dc.subject.keywordPlus | RAT-LIVER CELLS | - |
dc.subject.keywordPlus | CLOZAPINE TREATMENT | - |
dc.subject.keywordPlus | ADJUNCTIVE THERAPY | - |
dc.subject.keywordPlus | COX-2 INHIBITORS | - |
dc.subject.keywordPlus | INTERFERON-GAMMA | - |
dc.subject.keywordPlus | SEROTONIN | - |
dc.subject.keywordPlus | PATHWAY | - |
dc.subject.keywordAuthor | Cytokine | - |
dc.subject.keywordAuthor | Inflammatory response | - |
dc.subject.keywordAuthor | Tryptophan | - |
dc.subject.keywordAuthor | Tryptophan breakdown | - |
dc.subject.keywordAuthor | Schizophrenia | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.